Table 1.

List of selected target antigens with available trial results or currently under investigation

Antigen	Disease	Trial/Product and clinical results
CD19	B-cell malignancies	KTE-C19/Axicabtagene ciloleucel (NHL)a: 82% ORR, 54% CR, 42% with ongoing response after median follow-up of 15.4 months (ZUMA-1, n = 111) [7]
		CTL-019/Tisagenlecleucel (ALL <21 y)b: 81% CR, all MRD negative, RFS 80% and 59% at 6 and 12 months, respectively (ELIANA, n = 75) [11]
		CTL-019/Tisagenlecleucel (DLBCL)b: 53% ORR, 40% CR, RFS 74% at 6 months (JULIET, n = 99) [14]
		Park et al. (ALL ≥18 y): 83% CR, median EFS 6 months (n = 53) [25]
		JCAR017 (NHL): 75% ORR, 56% CR, 37% with CR at 6 months (results only reported for DLBCL cohort, n = 69) [15]
CD30	Hodgkin lymphoma, T‑cell lymphoma	Wang et al. (HL, ALCL): 0/18 CR, 7/18 PR, 1/18 SD, 10/18 NR [26]
		Ramos et al. (HL, ALCL): 3/9 CR, 3/9 SD, 3/9 NR [27]
CD22	B-cell malignancies	Fry et al. (ALL): 73% CR; CR also in 5/5 pts. with CD19− or CD19dim B‑ALL (n = 21) [28]
CD20	B-cell malignancies	Zhang et al. (NHL): 82% ORR, 55% CR (n = 11) [29]
BCMA	Multiple myeloma	Bb2121 (MM): 89% ORR; 100% ORR in pts. with >150 × 10^6 CAR T cells, 3/15 sCR, 1/15 CR, 7/15 VGPR, 4/15 PR [30]

Either the designated CAR T‑cell product reference (italic) or, if not applicable, the name of the first-author of the respective publication is shown

ALCL anaplastic large cell lymphoma, BCMA B-cell maturation antigen, CR complete remission, DLBCL diffuse large B‑cell lymphoma, EFS event-free survival, HL Hodgkin lymphoma, MRD minimal residual disease, NHL non-Hodgkin lymphoma, NR no response, ORR overall response rate, PR partial remission, RFS relapse-free survival, SD stable disease, sCR stringent complete remission, VGPR very good partial remission

^aMarketed as “Yescarta” in the United States

^bMarketed as “Kymriah” in the United States